Institute of Cancer and Genomic Sciences, University of Birmingham, B152TT, Birmingham, UK.
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Leukemia. 2023 Jan;37(1):102-112. doi: 10.1038/s41375-022-01744-5. Epub 2022 Nov 4.
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy caused by mutations in genes encoding transcriptional and epigenetic regulators together with signaling genes. It is characterized by a disturbance of differentiation and abnormal proliferation of hematopoietic progenitors. We have previously shown that each AML subtype establishes its own core gene regulatory network (GRN), consisting of transcription factors binding to their target genes and imposing a specific gene expression pattern that is required for AML maintenance. In this study, we integrate gene expression, open chromatin and ChIP data with promoter-capture Hi-C data to define a refined core GRN common to all patients with CEBPA-double mutant (CEBPA) AML. These mutations disrupt the structure of a major regulator of myelopoiesis. We identify the binding sites of mutated C/EBPα proteins in primary cells, we show that C/EBPα, AP-1 factors and RUNX1 colocalize and are required for AML maintenance, and we employ single cell experiments to link important network nodes to the specific differentiation trajectory from leukemic stem to blast cells. Taken together, our study provides an important resource which predicts the specific therapeutic vulnerabilities of this AML subtype in human cells.
急性髓细胞白血病 (AML) 是一种异质性血液恶性肿瘤,由编码转录和表观遗传调节剂以及信号基因的基因突变引起。其特征是造血祖细胞分化和异常增殖的紊乱。我们之前已经表明,每种 AML 亚型都建立了自己的核心基因调控网络 (GRN),由转录因子与其靶基因结合并施加特定的基因表达模式组成,这是 AML 维持所必需的。在这项研究中,我们将基因表达、开放染色质和 ChIP 数据与启动子捕获 Hi-C 数据相结合,定义了一个适用于所有 CEBPA 双突变 (CEBPA) AML 患者的精细核心 GRN。这些突变破坏了髓系细胞生成的主要调节剂的结构。我们鉴定了原代细胞中突变的 C/EBPα 蛋白的结合位点,我们表明 C/EBPα、AP-1 因子和 RUNX1 共定位,并维持 AML 的维持,我们还进行了单细胞实验,将重要的网络节点与从白血病干细胞到原始细胞的特定分化轨迹联系起来。总之,我们的研究提供了一个重要的资源,预测了这种 AML 亚型在人类细胞中的特定治疗弱点。